METHODS AND COMPOSITIONS FOR RAYNAUD DISEASE TREATMENT Russian patent published in 2017 - IPC A61K31/5575 A61P9/10 

FIELD: medicine.

SUBSTANCE: semi-solid composition of prostaglandin E1 for topical administration to a subject in need is used, wherein the treatment method comprises topical application of an effective amount of this prostaglandin E1 composition to the surface of the affected body part. At that, the total daily dose of prostaglandin E1, applied to the surface of the affected body part, is approximately 0.5 to 5.7 mg. Prostaglandin E1 for production of such semi-solid composition, which may also include suitable thickeners and penetration enhancers such as dodecyl-2(N,N-dimethylamino)-propionate (DDAIP). Preferably, the semi-solid topical composition has a room temperature at the time of application to the affected body part surface to avoid vasospasm triggering or exacerbation characteristic of the Raynaud phenomenon secondary to systemic sclerosis. The total daily dose of the semi-solid composition can be applied as needed or divided by 2-4 times a day.

EFFECT: no complications of systemic administration and the desired relief of the secondary Raynaud phenomenon in systemic sclerosis, improvement of quality of life, patient functions, reduction of finger ulceration, prevention of new finger ulcers, improvement of existing ulcers healing.

39 cl, 2 dwg, 4 tbl, 2 ex